NCT06510504 - Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Social Anxiety Disorder

Interventions

DRUG

225 mg BNC210

DRUG

Placebo

Trial Locations (21)

11229

AFFIRM-1 Study Site, Brooklyn

19063

AFFIRM-1 Study Site, Media

28211

AFFIRM-1 Study Site, Charlotte

30030

AFFIRM-1 Study Site, Decatur

32256

AFFIRM-1 Study Site, Jacksonville

32801

AFFIRM-1 Study Site, Orlando

33016

AFFIRM-1 Study Site, Miami Lakes

33319

AFFIRM-1 Study Site, Lauderhill

33607

AFFIRM-1 Study Site, Tampa

78737

AFFIRM-1 Study Site, Austin

90025

AFFIRM-1 Study Site, Los Angeles

91316

AFFIRM-1 Study Site, Encino

91403

AFFIRM-1 Study Site, Sherman Oaks

92037

AFFIRM-1 Study Site, La Jolla

92056

AFFIRM-1 Study Site, Oceanside

92103

AFFIRM-1 Study Site, San Diego

92591

AFFIRM-1 Study Site, Temecula

95124

AFFIRM-1 Study Site, San Jose

02114

AFFIRM-1 Study Site, Boston

02131

AFFIRM-1 Study Site, Boston

08540

AFFIRM-1 Study Site, Princeton